Rankings
▼
Calendar
TCRX FY 2021 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TCRX
TScan Therapeutics, Inc.
$69M
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$10M
+834.7% YoY
Gross Profit
$10M
100.0% margin
Operating Income
-$49M
-479.6% margin
Net Income
-$49M
-479.5% margin
EPS (Diluted)
$-2.03
Cash Flow
Operating Cash Flow
-$49M
Free Cash Flow
-$59M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$188M
Total Liabilities
$27M
Stockholders' Equity
$161M
Cash & Equivalents
$161M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$10M
$1M
+834.7%
Gross Profit
$10M
-$19M
+152.0%
Operating Income
-$49M
-$26M
-85.4%
Net Income
-$49M
-$26M
-86.1%
← Q4 2020
All Quarters
Q1 2021 →